Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Neith Corporation (6236.TWO)
Taichung, TW
Neith Corporation operates in diverse sectors, encompassing biotechnology, medical aesthetics, and preventive health solutions. The company provides a variety of nutritional supplements, including L-One, a liquid formula designed to support ocular well-being, and EPlus, a multi-enzyme blend. Additional nutritional offerings are marketed under the King One brand. Beyond supplements, Neith also offers genetic testing services. Its product portfolio extends to a wide array of wellness and energy-enhancing items, such as versatile mattresses (energy and dual-purpose), energy-infused masks, silicon gel necklaces, waistbands, heated energy stones, and massage tools. The company further supplies water purification systems and specialized Ganbanyoku energy stone spa beds. In the beauty segment, Neith presents a line of skincare products focused on cell regeneration and rejuvenation. Other offerings include energy-focused household items, as well as microcontrollers and their associated peripheral devices. Established in 1997, Neith Corporation was initially known as Come True Biomedical Inc. The company's headquarters are situated in Taichung, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-20.7% Q4'25: -27.9% (vs Q4'24)
-
EPS growth Biotechnology: +29.7%+118.5% ★ Q4'25: -30.4% (vs Q4'24)
-
FCF margin FCF growth · Biotechnology: +16.2%+17.1% Q4'25: +35.6% (vs Q4'24)
-
EBIT margin Biotechnology: +0.0%-2.6% Q4'25: +1.4% (vs Q4'24)
-
ROIC Biotechnology: -16.1%-4.5% ★ Q4'25: +2.2% (vs Q4'24)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q4'25: +0.0% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.95× ★ Q4'25: 1.44× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-22 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chun Yi Wu | Chairman and Chief Executive Officer | — | male |
| Michael Chen | Director of Finance and Accounting Department | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6236.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
